Dimerix Patent Victory
Dimerix Secures Critical US Patent for DMX-652, Extending Acute Kidney Injury Drug Protection to 2043
Anonymous
Key Points
1
Approximately 25% of patients develop acute kidney injury after on-pump cardiac surgery, highlighting the clinical need DMX-652 targets.
2
The DMX-652 patent is US 12,679,833, titled N-cyanopyrrolidines with activity as USP30 inhibitors, and includes a patent term adjustment adding about 677 days to extend protection to 11 April 2043.
3
DMX-652 was recently acquired as a Phase 2 ready asset and is supported by an open US IND, with plans to commence a Phase 2 trial for AKI related to cardiac surgery; the compound is formulated as an oral once-daily capsule.
4
A divisional patent application has been filed to broaden DMX-652 IP, potentially extending coverage to additional formulations, uses, or manufacturing processes.
5
Investors reacted positively to the patent milestone, with Dimerix shares rising about 4% in morning trading (around AUD 0.26).
Dimerix has locked in US patent protection for its drug candidate DMX-652 through April 2043, giving the Australian biotech a two-decade runway of exclusivity on a treatment targeting acute kidney injury. The patent, US 12,679,833, covers the compound's composition of matter and includes a 677-day patent term adjustment — a significant boost for a drug still in early clinical stages, according to Kalkine Media.
Investors responded quickly. Dimerix shares rose about 4% in morning trading to around AUD 0.26 after the announcement, according to Kalkine.
What DMX-652 Does and Why It Matters
DMX-652 is a USP30 inhibitor. In plain terms, it blocks a protein that interferes with the body's ability to clear out damaged cell parts. By blocking USP30, the drug helps kidney cells remove faulty mitochondria — the energy-producing structures inside cells — before they cause serious harm. This process is called mitophagy, according to Kalkine.
The target condition is acute kidney injury, or AKI, linked to cardiac surgery. About 25% of patients who undergo on-pump cardiac surgery develop AKI, according to Tipranks. There are currently no approved drugs that prevent it. DMX-652 would be taken as an oral once-daily capsule, making it easy to use in a hospital setting.
Patent Runs to 2043 With 677 Extra Days of Protection
The core patent was granted by the US Patent and Trademark Office. Its base term would have expired earlier, but a patent term adjustment added roughly 677 days of extra protection, pushing the expiry to 11 April 2043, according to Kalkine. That adjustment is granted when government processing delays slow down the patent review.
Dimerix also filed a divisional patent application to widen its IP coverage. That move could extend protection to additional formulations, new uses, or manufacturing methods, according to Grafa. Tipranks described DMX-652 as a "first-in-class" asset, meaning no approved drug currently works in the same way.
Phase 2 Trial Plans Already in Motion
Dimerix acquired DMX-652 as a Phase 2-ready asset, meaning most of the early safety testing is already done. The company has an open US Investigational New Drug application — the required FDA clearance to run clinical trials — and GMP-grade drug supply ready to go, according to Kalkine Media.
A Phase 2 trial in AKI related to cardiac surgery is now being planned. DMX-652 sits alongside DMX-200, Dimerix's lead asset, which is already in Phase 3 development for kidney disease, according to Grafa. The two drugs together give the company a pipeline that spans both prevention and treatment of kidney conditions.
Dimerix Still Needs Outside Funding to Move Forward
Despite the positive news, Dimerix is still a clinical-stage company with no product revenue. It relies on external capital to fund operations and trials, according to Kalkine. That financial dependence is a key risk as it scales up development costs for two active programs.
The company is actively pursuing partnerships for global development and commercialization of DMX-652. Securing a partner could reduce the funding burden and accelerate the path to a Phase 2 readout. For now, the 2043 patent gives any potential partner a long window of market exclusivity to make a deal attractive, according to Tipranks.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
2
Reach
12
Topics
A
AnonymousAuthor